{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:11:07Z","timestamp":1784815867609,"version":"3.55.0"},"reference-count":14,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine the effectiveness and safety of surgery, chemotherapy, or radiotherapy for treating post-chemotherapy residual mass in advanced testicular seminoma in terms of overall survival and progression-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a search strategy in MEDLINE (OVID), EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to nowadays. We assessed the risk of bias and performed this review according to the recommendations of the Cochrane Collaboration and following the PRISMA Statement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Within the included studies, there are 239 patients with germ cell carcinoma, all in an advanced stage of the disease (IIa,IIb, IIc, or III) and where 100% are pure seminomas. The interventions were radiation therapy, immediate resection after the first positive PET, other salvage therapy as second or third chemotherapy for residual masses, and a high dose of chemotherapy and autologous stem cell transplantation. The median progression-free survival in the observation arm was 39.4\u2009months in the very high-risk group and 40\u2009months in the high-risk group, whereas it was not reached for the radiotherapy arm. Also, a new chemotherapy scheme had progression-free survival in a 10-year follow-up of 94.2%. The overall survival for the high-risk group radiotherapy versus observation was not significant (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.47), similar to the very high-risk subgroup (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.42). The reported complications are due to surgical management and chemotherapy toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Evidence on the management of post-chemotherapy residual retroperitoneal masses in advanced seminoma is limited and of low certainty. Available studies are few and heterogeneous, precluding definitive conclusions regarding progression-free or overall survival. Current findings support individualized treatment decisions, while further prospective studies are needed to better define optimal management strategies and long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603261467519","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:07:43Z","timestamp":1784653663000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of salvage therapy in residual retroperitoneal masses in advanced testicular seminoma: A systematic review"],"prefix":"10.1177","author":[{"given":"Maria Paula","family":"Gomez","sequence":"first","affiliation":[{"name":"UROGIV Research Group, School of Medicine, Universidad del Valle, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6945-8261","authenticated-orcid":false,"given":"Herney Andres","family":"Garcia-Perdomo","sequence":"additional","affiliation":[{"name":"UROGIV Research Group, School of Medicine, Universidad del Valle, Cali, Colombia"},{"name":"Division of Urology\/Urooncology, Department of Surgery, School of Medicine, Universidad del Valle, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","unstructured":"Giannatempo P Greco T Mariani L et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol 2015; 26(4): 657\u2013668. https:\/\/doi.org\/10.1093\/annonc\/mdu447","DOI":"10.1093\/annonc\/mdu447"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602020"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.454"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"Bachner M Loriot Y Gross-Goupil M et al. 2-\u00b9\u2078fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23(1): 59\u201364. https:\/\/doi.org\/10.1093\/annonc\/mdr052","DOI":"10.1093\/annonc\/mdr052"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Cathomas R Klingbiel D Bernard B et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol 2018; 36(34): JCO1800210. https:\/\/doi.org\/10.1200\/JCO.18.00210","DOI":"10.1200\/JCO.18.00210"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000060121.33899.4b"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Rice KR Beck SD Bihrle R et al. Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection. J Urol 2014; 192(5): 1397\u20131402. https:\/\/doi.org\/10.1016\/j.juro.2014.04.097","DOI":"10.1016\/j.juro.2014.04.097"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Murthy V Johnny C Huddart R. Positron emission tomography-positive post-chemotherapy seminoma masses: time to reevaluate the role of radiotherapy? J Clin Oncol 2019; 37(11): 937\u2013938. https:\/\/doi.org\/10.1200\/JCO.18.01991","DOI":"10.1200\/JCO.18.01991"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Murthy V Karmakar S Carlton J et al. Radiotherapy for post-chemotherapy residual mass in advanced seminoma: a fluorodeoxyglucose positron emission tomography-computed tomography-based risk-adapted approach. Clin Oncol 2021; 33(7): e315\u2013e321. https:\/\/doi.org\/10.1016\/j.clon.2021.01.009","DOI":"10.1016\/j.clon.2021.01.009"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","unstructured":"Becherer A Santis MD Karanikas G et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 2005; 54(2): 284\u2013288. https:\/\/doi.org\/10.1016\/j.ejrad.2004.07.012","DOI":"10.1016\/j.ejrad.2004.07.012"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Giannis M Aristotelis B Vassiliki K et al. Cisplatin-based chemotherapy for advanced seminoma: report of 52 cases treated in two institutions. J Cancer Res Clin Oncol 2009; 135(11): 1495\u20131500. https:\/\/doi.org\/10.1007\/s00432-009-0596-2","DOI":"10.1007\/s00432-009-0596-2"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00111-1"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Campetella M Ragonese M Gandi C et al. Surgeons\u2019 fatigue in minimally invasive and open surgery: a review of the current literature. Urologia 2025; 92(1): 161\u2013168. https:\/\/doi.org\/10.1177\/03915603241300226","DOI":"10.1177\/03915603241300226"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Bizzarri FP Campetella M Russo P et al. Prognostic value of PLR SIRI PIV SII and NLR in non-muscle invasive bladder cancer: can inflammatory factors influence pathogenesis and outcomes? Cancers 2025; 17(13): 2189. https:\/\/doi.org\/10.3390\/cancers17132189","DOI":"10.3390\/cancers17132189"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261467519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261467519","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261467519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:58:27Z","timestamp":1784815107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261467519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":14,"alternative-id":["10.1177\/03915603261467519"],"URL":"https:\/\/doi.org\/10.1177\/03915603261467519","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"03915603261467519"}}